Sulfonylureas and similarly acting rapid insulin secretagogues have long been available to manage type 2 diabetes. These agents have a well understood mechanism of action and are in large part well tolerated. However, sulfonylurea therapy is unlikely to sustain adequate long-term glycemic control and has potential side effects, including hypoglycemia and weight gain. Additional concerns exist regarding detrimental effects of certain sulfonylureas on ischemic preconditioning and cardiac outcomes. Fortunately, newer agents such as glimepiride appear less likely to adversely affect the myocardium. These agents can often be used successfully as one component of combination therapy for diabetes management.
KeywordsMetformin Hypoglycemia Glycemic Control Sulfonylurea Exenatide
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.CDC’s Diabetes Program: Data & Trends — Prevalence of Diabetes. http://www.cdc.gov/diabetes/statistics/prev/ national/.gpersons.htm. Accessed June 30, 2006.Google Scholar
- 3.U.K. Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group [no authors listed]. Diabetes 1995, 44:1249–258.Google Scholar
- 5.Riddle MC: Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005, 34:77–98. Data from multiple clinical trials suggest that combinations of insulin secretagogues, insulin-sensitizing agents, and insulin are often necessary to adequately control glycemia in type 2 diabetes. This paper outlines the rationale for and effectiveness of such strategies in diabetes management.PubMedCrossRefGoogle Scholar
- 8.Morello CM, Edelman SV: Exenatide. Practical Diabetology 2006, 25:6–18.Google Scholar
- 11.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:837–853.Google Scholar
- 13.Bell DS: Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004, 26:1714–1727. This review article provides a comprehensive overview of sulfonylurea mechanism of action, effectiveness, side effects, and rationale for use.PubMedCrossRefGoogle Scholar
- 17.Simonson DC, Kourides IA, Feinglos MN, et al.: Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM: results of two multicenter, randomized, placebo-controlled clinical trials. Diabetes Care 1997, 20:597–606.PubMedCrossRefGoogle Scholar
- 22.American diabetes association policy statement: the UGDP controversy [no authors listed]. Diabetes Care 1979, 2:1-3.Google Scholar
- 27.Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group [no authors listed]. Lancet 1998, 352:854–865.Google Scholar